OTTAWA, ON – CSL Behring Canada announced that HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), is now available in all of Canada. HAEGARDA is a subcutaneous C1 esterase inhibitor (C1-INH) therapy indicated for routine prevention of Hereditary Angioedema (HAE) attacks in adolescent and adult patients.1 HAE patients have absent or low levels of endogenous or...
treatment News
Jackson Center, PA – Halberd Corporation (OTC-PINK: “HALB“) received notification from the Ference Law Firm in Pittsburgh of a Notice of Allowance, by the US Patent Office, for the treatment of Cockayne Syndrome. Cockayne Syndrome is a fatal autosomal recessive neurodegenerative disorder which causes premature aging and severely impaired development...
LEHI, Utah — Halia Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class anti-inflammatory therapies, today announced six poster presentations and one oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition taking place in Orlando, Florida, from December 6-9, 2025. Ofirnoflast is a novel, oral, allosteric NEK7 inhibitor designed...
SAN DIEGO, CA — Halozyme Therapeutics, Inc., today announced that argenx received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) injection co-formulated with Halozyme’s ENHANZE® drug delivery technology for subcutaneous (SC) use for the treatment of adult patients with generalized myasthenia gravis...
SAN DIEGO, Calif. — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced that Takeda received European Commission (EC) approval for HYQVIA® [Immune Globulin Infusion 10% (Human)] co-formulated with Halozyme’s ENHANZE® drug delivery technology as maintenance therapy in patients of all ages with chronic inflammatory demyelinating polyneuropathy (CIDP) after stabilization with intravenous...
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China – Harbour BioMed (“HBM”, HKEX: 02142) today announced positive topline results from its Phase 2 proof-of-concept clinical trial of batoclimab (HBM9161) in Chinese generalized myasthenia gravis (gMG) patients. Data received from the Phase 2 Study, as the first clinical evidence of anti-FcRn therapies in Chinese patients, showed...
PLYMOUTH MEETING, Pa., March 19, 2021 — Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced publication of a white paper sharing outcomes from a Summit on Sleep...
PLYMOUTH MEETING, Pa. — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced the presentation of initial open-label extension (OLE) data from the company’s ongoing Phase 3 ARGUS trial investigating EPX-100 (clemizole hydrochloride) for the treatment of Dravet syndrome (DS), which showed clinically meaningful reductions in seizure activity in participants with...
PLYMOUTH MEETING, PA. — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to pitolisant for the treatment of Prader-Willi syndrome (PWS). “The decision to grant Orphan Drug designation to pitolisant indicates that it could be a promising treatment option...
Chicago, Ill. – Scientists at Harvard University and the University of Illinois Chicago have developed an antibiotic that could give medicine a new weapon to fight drug-resistant bacteria and the diseases they cause. The antibiotic, cresomycin, described in Science, effectively suppresses pathogenic bacteria that have become resistant to many commonly...